Abstract. The assessment of tumor-associated antigens (TAA) recognized by T lymphocytes is a prerequisite for diagnosis and immunotherapy of melanoma. Different reverse transcription-polymerase chain reaction (RT-PCR) protocols allowing the quantification of the TAA mRNA expression in the solid tumor or the detection of circulating melanoma cells have been described. We have recently shown a positive correlation between the amount of specific product formed by RT-PCR and the staining intensity in immunohistochemical analysis of the corresponding sample. Here we describe a quantification procedure based on the direct digitization of the PCR products after separation on ethidium bromide-stained agarose gels, followed by computer-assisted densitometry. To standardize our method, we examined the linear range of the densitometric quantification procedure as reflected by the correlation of signal intensity to the amount of the corresponding DNA. As an internal measure for the so-termed 'effective' cDNA in the different samples after RNA isolation and reverse transcription, a ß-actin PCR was introduced. Subsequently, we chose four sets of primers for the melanomaassociated antigens MAGE1, tyrosinase, Melan A/MART-1 and gp100/Pmel17 and performed PCR analysis over a range of cycle numbers. In each case, the amplification rate remained constant up to at least 26 cycles under the respective conditions. Plotting the logarithm of the amount of product against the cycle number yields a slope that equals the logarithm of the amplification rate. The amount of starting material can be determined from the intercept with the ordinate. In summary, the method introduced in the present work allows the quantification of TAA in melanoma which might be important for the monitoring of disease. Technically the method is sound and sensitive, avoids post-PCR manipulations and can be performed with the standard equipment of a molecular biology laboratory. It can be applied also to other solid tumors and leukemias.
Introduction
Melanoma is an immunogenic tumor entity. In the last decade, various TAA in melanoma have been characterized by the screening of expression libraries by cytotoxic T lymphocytes (1, 2) by peptide elution (3) or by the serological screening of cDNA expression libraries (SEREX) (4) . Peptides derived from these TAA are potential immunotherapeutical agents. It has been shown that mere peptides applied intradermally (5, 6) , or peptides pulsed on dendritic cells (7) are able to elicit CTL responses in vivo and can even lead to clinical remissions. Since immunointervention can only lead to success if the target antigen is definitely present on the tumor, it is mandatory to have a reliable and, if possible, quantitative method that allows to assess the expression of the respective tumor antigen in melanoma tissues.
Methods available for this purpose can be divided into direct methods that allow to monitor antigen expression at the level of protein, and indirect methods that provide information at the level of the transcript. Direct methods, like immunohistochemistry, immunoblotting and ELISA, reflect best the in vivo situation but require the availability of specific antibodies, and furthermore are relatively sophisticated and time-consuming procedures.
Indirect methods, like Northern blotting, RNase protection assay and reverse transcription-polymerase chain reaction (RT-PCR), are also suitable for monitoring antigen expression in tissues (8) (9) (10) , since in most cases there is a good correlation between the amount of mRNA expressed from a specific gene and the corresponding amount of protein that finally results from its translation. Of these indirect methods, the RT-PCR is especially attractive because it can be applied even to very small biopsy samples and is a relatively simple procedure. Qualitative RT-PCR has been established as a standard procedure in molecular biology, whereas quantification of the RT-PCR products is often cumbersome and difficult to be achieved. Problems are internal and external standards, interand intra-center reproducibility, measurement of the amount of cDNA and its digitization. In this study, we attempted to establish an easy-to-handle and widely applicable method, which can be performed in each molecular biology laboratory and gives valid results in a broad range of cDNA amounts.
Two alternative approaches can be taken to analyze quantitative differences in gene expression among different samples by RT-PCR, namely the competitive and the noncompetitive RT-PCR. Competitive RT-PCR is based on the use of an external standard added to the sample prior to analysis, that is amplified with the same pair of primers as the transcript under investigation, but yields a fragment size different to that from the test fragment. Quantification is performed by titrating defined amounts of the standard mRNA against a constant amount of the experimental mRNA. To obtain reliable results, it is essential that target and standard fragments amplify with the same efficiency.
Non-competitive RT-PCR relies exclusively on the linear relationship between the starting amount of target RNA and the final quantity of product formed during PCR before reaching a plateau phase of the amplification. Different approaches have been described to obtain quantification of products generated by non-competitive RT-PCR, such as radio-or chemiluminescence labelling of either the PCR product itself or a probe hybridized to it, respectively (11) (12) (13) . These attempts, however, are cost and labour intense.
Recently, real time RT-PCR performed either by light cycler (Roche) or TaqMan (Perkin-Elmer) became popular. These methods require expensive devices which are not accessible in each institution and which might not necessarily yield more information than conventional RT-PCR methods.
Subsequently, we focused in this study on the application of the RT-PCR method on melanoma TAA for the selection and the monitoring of patients undergoing peptide vaccination at our institution. Since immune reponses can only be triggered by TAA expression above certain threshold levels (14) , quantitative assessment of the TAA mRNA expression is mandatory for successful immunotherapeutical interventions.
Materials and methods

Materials.
Tissue samples were obtained either by needle biopsy under sonographic guidance or by surgical resection and were immediately frozen in liquid nitrogen. All patients gave their informed consent to have the expression of melanoma associated antigens assessed in their melanoma tissues.
Restriction enzymes and T4 ligase were obtained from Gibco (Gaithersburg, MD) or New England Biolabs (Beverly, MA) respectively. All other chemicals were obtained from Sigma (St. Louis, MO), or Roth (Karlsruhe, Germany) in analytical quality or otherwise highest quality available.
RT-PCR.
Total RNA was isolated either from tumor samples immediately frozen in liquid nitrogen after resection or biopsy, or from melanoma cell lines, using the RNasy kit according to the manufacturer's instructions (Qiagen, Chatsworth, CA). The success of the isolation was monitored by agarose gel electrophoresis and subsequent UV detection of the ethidium bromide-stained RNA. Approximately 2 µg of each sample were subjected to cDNA synthesis using the Ready-to-Go first-strand synthesis kit (Pharmacia, Freiburg, Germany) containing oligo(dT) primer for the reverse transcription. In order to confirm that the same amount of 'effective' (see below) cDNA was applied to the subsequent amplification of melanoma-associated antigens, a ß-actin PCR was performed. The reaction mixture was composed of a standard PCR buffer (Tris-HCl, 10 mM, pH 8.3; KCl, 50 mM) containing magnesium chloride, 2.5 mM, deoxynucleotide triphosphates, 250 µM each, the forward and the reverse primer (Table I) , Table I . Primer sequences and conditions. 
100 ng each, and 2 µl of the first strand reaction mixture, corresponding to about 1 ng of template cDNA (rough estimate, based on the assumption of 2.5% of the total RNA being mRNA and a reverse transcription efficiency of 40%), in a final volume of 50 µl under a confluent layer of mineral oil. The reaction was started after an initial denaturation step (95˚C for 5 min) by the addition of 2.5 U AmpliTaq (PerkinElmer, Norwalk, CT), followed by 22 amplification cycles (1 min denaturation at 94˚C, 1 min hybridization at 68˚C, and 1 min elongation at 72˚C) and a final elongation step (72˚C for 10 min). The amount of product formed during the PCR was analyzed and quantified as described below. Under the assumption of an equal expression rate of ß-actin in all samples under investigation, a correction factor f corr was calculated for each individual sample using the formula:
where Vst is the integration value obtained for a standard sample run along with the samples under investigation and Vi is the integration value obtained for the respective sample to be standardized. Multiplication of the obtained correction factor with the volume of the RT sample initially subjected to the PCR resulted in the volume of the respective sample to be applied in the RT-PCR for the quantitative assessment of the expression rates of melanoma-associated antigens. The success of this normalization procedure was monitored by a second ß-actin PCR employing the corrected sample volume under otherwise identical conditions. Subsequently, the expression of the melanoma-associated antigens Melan A/MART-1, tyrosinase, MAGE1 and gp100/Pmel17 was assessed by PCR under conditions essentially as described above for the ß-actin PCR, using the respective primers, annealing temperatures and elongation times given in Table I . The identity of the amplification products was confirmed by appropriate restriction analysis.
Quantification of the PCR products. The amplified products were analyzed by electrophoresis on 1.5% agarose gels containing 0.4 µg/ml ethidium bromide. Subsequent digitization was performed employing an Eagle Eye II documentation system (Stratagene, La Jolla, CA). For the quantification of the amount of the amplified product we used the software NIH Image Version 1.59, run on an Apple Macintosh Performa 5300 or SCION Imaging Software  (release ß 4.0.2) run on a PC with a PIII processor, and in particular the 'gel plotting macro' that is provided with both programs. In brief, the separate lanes of the analytical gel were scanned for the staining intensity of the obtained bands, with the relevant signals being transformed into peaks in a line diagram. The area under each peak was determined and taken as the direct measure for the quantity of the respective cDNA fragment. For absolute quantification, defined amounts of respective standards (see below) were run along in the same analysis and the obtained signal intensities were compared.
Construction of the standards. The cDNAs corresponding to the open reading frames of Melan A/MART-1 (forward primer, 5'-TGGGATCCATGCCAAGAGAAGATGCTCAC-3'; reverse primer, 5'-TTGAATTCAAGCAAAAGTGTGA GA-3'), tyrosinase (forward primer, 5'-TGGGATCCATGCT CCTGGCTGTTTTG-3'; reverse primer, 5'-TGGAATTCTC TGGGAACCTGGA-3'), and gp100/Pmel17 (forward primer, 5'-AAGAATTCAATGGATCTGGTGCTAA-3'; reverse primer, 5'-GGGAATTCTGTCAACTCCAGGAAA-3') were amplified via RT-PCR, using the primers indicated in brackets. These primers contained restriction sites for BamHI or EcoRI that were employed for the insertion of the respective PCR product into the multiple cloning site of the plasmid vectors pRSET A (Melan A/MART-1, tyrosinase) and pRSET C (gp100/Pmel17). The 421 bp fragment derived from the diagnostic RT-PCR with MAGE1-specific primers (Table I) was directly cloned into the vector pGemT (Boehringer Mannheim) without further processing. The resulting constructs served as standards in the respective RT-PCR analyses.
Results
Validation of the quantification procedure. We first examined the linear range of the quantification process based on computer aided densitometry as described in Materials and methods. A standard curve was set up by analyzing a dilution series of linearized pcDNA1Amp DNA over a range of 1 µg to 2 ng per lane, followed by electronic quantification. We found a stringent linear relationship between the amount of DNA and corresponding signal intensities over the range of 2-64 ng loaded per lane (Fig. 1) . Care was taken not to exceed this range in the following analysis.
Establishment of the normalization procedure for the 'effective' cDNA. Under the assumption that the expression of ß-actin is very similar in each individual sample of a given series under investigation, we introduced a ß-actin RT-PCR as a measure for the 'effective' cDNA in each sample. The term 'effective' cDNA is meant to describe the amount of amplifiable cDNA that results from the RNA extraction and subsequent reverse transcription procedure with a given sample.
First, we determined the range of the constant amplification rate for the ß-actin RT-PCR by quantifying the amount of DNA formed after each additional round of amplification between 20 and 28 cycles of the PCR (Fig. 2) . No change in the amplification rate was evident up to at least 400 ng of product formed per 50 µl reaction volume. Using a panel of different melanoma biopsies we found 22 cycles of amplification to be optimal for the analysis, since every sample under investigation produced a detectable signal while none of them exceeded the range of the constant amplification rate. On the basis of the fact, that during the course of PCR amplification under conditions of constant amplification rate the ratio of amplified fragments in two separate simultaneously amplified samples does not change and assuming that each sample has the same expression level of ß-actin mRNA, we used the result of ß-actin RT-PCR quantification to determine the amount of 'effective' cDNA (see above) produced by RNA isolation and reverse transcription. We performed a second ß-actin RT-PCR with an adjusted amount of cDNA applied to the analysis in order to obtain equal signal intensities with all samples with a total yield of about 250 ng ß-actin amplified per 50 µl reaction volume. The result of such a normalization attempt is shown in Fig. 3 . After adjusting the amounts of cDNA the variation in the ß-actin RT-PCR between different samples typically did not exceed 30%.
In order to be able to compare the results of separately performed amplification series we constructed cDNA standards containing the whole open reading frame of the respective gene products, cloned into the plasmid vectors The amounts of the amplification products were assessed as described and are given as the total amount of product formed in a 50 µl reaction volume. Linear regression was performed and showed a constant rate of amplification up to 24 cycles. pRSET A, pRSET C or pGemT, respectively. These constructs proved to be useful for both, being an external standard as well as serving for the calibration of the quantification procedure.
Kinetics of PCR for melanoma associated antigens.
After standardization of the respective samples we investigated the kinetics of the melanoma antigen RT-PCRs. The primer sets for the different antigens were selected such that forward and reverse primers were derived from different exons of the gene in question, in order to avoid erroneous results due to amplification of contaminating genomic DNA. Restriction analysis was performed to verify the identity of the amplified products. In all cases we found the predicted restriction fragment sites.
The different reactions displayed similar kinetics, with an initial phase of constant amplification rate, that starts to decrease after about 400 ng of product have been formed per 50 µl reaction volume, finally ending up in a plateau phase. By plotting the logarithm of the amount of product formed during the phase of the PCR with a constant amplification rate versus the respective number of cycles, a slope is obtained by linear regression that equals the logarithm of the amplification rate of the respective PCR. Rates obtained this way for the amplification of MAGE1, tyrosinase, Melan A/ MART-1 and gp100/Pmel17 were 1.84-, 1.66-, 1.82-and 1.65-fold per cycle, respectively. The intercept with the ordinate obtained at the same time represents the logarithm of the starting amount of amplifiable target cDNA, that can therefore also be determined (Fig. 4) . For example, the starting amount of gp100 mRNA corresponding to the cDNA fragment amplified in the experiment presented in Fig. 4d is computed to be 10 -3.435 ng (=367 fg).
Differences in the yield of PCR fragments between different samples after normalization through ß-actin PCR are supposed to reflect differential expression levels of the respective cDNA under investigation, but could theoretically also be explained by a variation of the amplification rate for the PCR reaction among the different samples, due to the presence of interfering material in one of the samples. To exclude this, we performed a series of experiments where we mixed samples with apparently different expression levels for the mRNA under investigation, and compared the results of the respective PCR with that obtained with the pure samples. In each case, the signal intensity obtained with the mixture was very close to the calculated mean value of the two samples analyzed separately (for a typical experiment, see Fig. 5 ). This result strongly supports the initial presumption, that the yield of PCR fragment is mainly determined by the abundance of the respective mRNA in the starting material. 
Discussion
RT-PCR assays are now utilized for a wide range of applications. The technique has been applied to various subjects such as the analysis of cytokine production of T cells (11) , the expression of receptors in human cancers (15) or the detection of circulating tumor cells in peripheral blood (16) . To find a reliable marker for minimal residual disease after therapy or the risk for the development of metastatic disease, several groups performed RT-PCR for melanoma-associated TAA using peripheral blood of melanoma patients. Detection of circulating melanoma cells (CMC), however, did not correlate with the staging of the disease at the time of diagnosis or with the clinical course of patients (16) . RT-PCR results were difficult to reproduce in an interlaboratory comparison (17) . A multiple CMC analysis repeated at a 2-h interval revealed rather fluctuating results (16) . In summary the occurrence of melanoma cells in the peripheral blood seems to be a discontinuous phenomenon and screening for CMC is currently not recommended for clinical use (18) .
Therefore the present study focused on the development of a convenient tool that could be used to obtain quantitative data about the expression of potential T cell antigens in human melanoma tissues. The assessment of melanoma-associated antigens is of particular interest as these antigens have currently been used for clinical vaccination studies (5) (6) (7) . For the selection as well as for the follow up of the respective patients it is highly desirable to have a reliable method to assess tumor antigen expression in a quantitative manner.
A number of compelling reasons favours the use of RT-PCR for this application when compared to alternative methods. First, the superior sensitivity of the PCR technique is sufficient for the detection of even minute amounts of mRNA coding for TAA. The amount of tumor tissue for analysis is usually limited, often a fine needle biopsy is the only material provided. This usually excludes the application of detection procedures not based on PCR for this purpose at the transcript level. Second, the PCR technique allows to process many samples simultaneously and therefore is suitable for the screening of a large number of patients. Finally, a particular advantage is the potentially immediate establishment of a RT-PCR after the identification of the DNA sequence of a new, potentially relevant T cell antigen, since a pair of primers can be readily designed. In contrast, the generation of a new monoclonal antibody requires several months of intensive screening efforts by a specialized team, with an uncertain outcome.
There are, of course, arguments against the use of RT-PCR for the present purpose. Probably the most stringent is that RT-PCR reflects the situation at the level of the transcript and fails to detect any impairment of processes relevant for the protein expression that occur downstream of transcription. Several authors report high correlation between RT-PCR and immunohistochemistry (10, 19) , indicating that such an impairment does not present a frequent problem. However, discrepancies have been found in some cases (20) . In our own recent work (6) , an almost perfect correlation between the results obtained with RT-PCR on the one hand and immunohistochemical analysis on the other was observed (n=20, one moderate deviation). The failure to detect the antigen by immunohistochemistry in a PCR-positive sample is not necessarily due to impairment of processes downstream of transcription. It might reflect the higher sensitivity of the RT-PCR as compared to immunohistochemistry. In the recent study we found a heterogeneic expression of Melan A/MART-1 and tyrosinase in some of the samples under investigation by means of immunohistochemistry (6) . Therefore, RT-PCR and immunohistochemistry can be considered complementary tests for the assessment of antigen expression in tumors.
Reverse transcription is influenced by the yield and integrity of the RNA, resulting in a specific amount of cDNA that can serve as a template in the amplification procedure. This amount of cDNA was termed 'effective' cDNA. In the present study we used a normalization procedure to quantify the concentration of 'effective' cDNA and to subsequently adjust the amount of sample subjected to the analysis. Furthermore, we constructed synthetic standards that are used to compare the results from different amplification series. Every PCR reaction under investigation displayed a constant amplification rate until at least 400 ng of amplified fragment were formed per 50 µl reaction volume. Since our present experimental set up allows the quantification down to at least 2 ng per band on an agarose gel, the range of valid quantification of the target mRNA covers almost two orders of magnitude when using a fixed cycle number for the analysis and can be further increased by varying the latter. For obtaining comparable results one should choose a fixed number of amplification cycles in the range of linear amplification, that has to be determined prior to each individual PCR strategy.
In an earlier study we classified the gene expression levels of melanoma antigens into three categories: no expression, weak expression and high expression. After the present validation of the procedure we are confident, that the method allows reliable quantification of the amount of transcript under investigation, consequently leading to a more accurate determination of the expression level. This seems to be of particular importance, as one group showed most recently that CTL induction can only be induced by overriding certain antigeneic treshold levels (14) .
The method described here relies on the availability of a video documentation system for the digitization of ethidiumbromide-stained agarose gels in combination with a freeware program available through the Internet for the quantification of the signal. It should also be possible to perform a semiquantitative variant of the procedure without such an equipment, by performing normalization and subsequent quantification of RT-PCR yield for the transcripts under investigation via comparison by-eye against known standards. The quantification procedure avoids the costs of chemiluminescence detection, the use of radioactive detection systems and of expensive real-time PCR devices for this purpose.
We conclude that the method described here provides a useful and easy to handle procedure for the assessment of the expression of melanoma-associated antigens. The approach can, of course, also readily be adapted to a wide range of other applications. The particular strength of the present method is the experimental simplicity of the approach that reduces costs and hands-on time and makes it feasible to assess a large number of samples simultaneously.
